Merck & Co Inc
NYSE:MRK
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
96.31
132.96
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Merck & Co Inc
Merck & Co Inc
Stock-Based Compensation
Merck & Co Inc
Stock-Based Compensation Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Stock-Based Compensation | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Merck & Co Inc
NYSE:MRK
|
Stock-Based Compensation
$741m
|
CAGR 3-Years
16%
|
CAGR 5-Years
14%
|
CAGR 10-Years
10%
|
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Stock-Based Compensation
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Stock-Based Compensation
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
|
Pfizer Inc
NYSE:PFE
|
Stock-Based Compensation
$698m
|
CAGR 3-Years
-11%
|
CAGR 5-Years
0%
|
CAGR 10-Years
3%
|
|
|
Zoetis Inc
NYSE:ZTS
|
Stock-Based Compensation
$72m
|
CAGR 3-Years
8%
|
CAGR 5-Years
1%
|
CAGR 10-Years
10%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Stock-Based Compensation
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Merck & Co Inc
Glance View
Nestled in the heart of the pharmaceutical industry, Merck & Co., Inc. stands as a titan of innovation and healthcare. Established in 1891, the company has grown and evolved, driven by a mission to discover, develop, and provide innovative products and services that save and improve lives around the world. At the core of Merck’s operations is its commitment to research and development (R&D), which serves as the lifeblood of its product pipeline. With billions poured annually into R&D, Merck seeks to uncover new medical breakthroughs that address unmet medical needs across diverse therapeutic areas, such as oncology, vaccines, infectious diseases, and diabetes. This relentless pursuit of scientific advancement is not only a testament to Merck’s commitment to health but also a critical factor in maintaining its competitive edge in a crowded market. Merck's business model is elegantly straightforward yet highly structured. Primarily, the company's revenue streams are powered by the sales of prescription medications and vaccines that emerge from their exhaustive research efforts. Products like Keytruda, a cancer immunotherapy, and Gardasil, a vaccine for human papillomavirus, are standout performers, championing Merck's ability to penetrate high-value markets and secure regulatory approvals across the globe. Beyond the development and sale of pharmaceuticals, Merck generates additional revenue through collaborations and partnerships with other companies, leveraging co-development and marketing agreements to extend its reach. Underpinning Merck's financial model is its rigorous approach to cost management and strategic acquisitions, which bolster its robust product line-up and keep the engines of growth humming. This strategic orchestration ensures that while Merck fulfills its corporate mission, it also aligns with shareholder interests, reflecting a harmonious balance that has supported its storied legacy.
See Also
What is Merck & Co Inc's Stock-Based Compensation?
Stock-Based Compensation
741m
USD
Based on the financial report for Sep 30, 2024, Merck & Co Inc's Stock-Based Compensation amounts to 741m USD.
What is Merck & Co Inc's Stock-Based Compensation growth rate?
Stock-Based Compensation CAGR 10Y
10%
Over the last year, the Stock-Based Compensation growth was 19%. The average annual Stock-Based Compensation growth rates for Merck & Co Inc have been 16% over the past three years , 14% over the past five years , and 10% over the past ten years .
You don't have any saved screeners yet
